This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Vivimed Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve 31st december 2025 results
VIVIMEDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.7 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vivimed Labs has informed BSE that its Board of Directors will meet on Friday, 13 February 2026 at Hyderabad. The agenda includes considering and approving the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025. Any other business items may also be taken up during the meeting. This is a routine compliance filing under SEBI Listing Regulations.
This is a standard pre-results intimation with no new information on business performance. Investors should watch for the actual Q3 FY26 numbers, which will be released after the board meeting on 13 February 2026.
| Q3 FY26 | Q3 FY25 | Change | |
|---|---|---|---|
| Revenue | ₹15.99 Cr | ₹36.51 Cr | −56.2% |
| Operating profit | −₹16.55 Cr | −₹6.04 Cr | loss widened |
| Profit after tax | −₹16.55 Cr | −₹5.98 Cr | loss widened |
| EBITDA margin | -68.3% | 2.9% | −71.2 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.